Kazia Therapeutics (KZIA) Net Income towards Common Stockholders (2009 - 2017)
Kazia Therapeutics' (KZIA) quarterly Net Income towards Common Stockholders came in at -$8.0 million in Q2 2017, up 11.01% YoY from -$7.2 million in Q2 2016, and up 11.42% on a QoQ basis from -$9.0 million in Q4 2016.
Kazia Therapeutics (KZIA) Net Income towards Common Stockholders (2009 - 2017) Analysis & Trends
Kazia Therapeutics (KZIA) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$8.0 million in Q2 2017.
- Quarterly Net Income towards Common Stockholders rose 11.01% year-over-year to -$8.0 million in Q2 2017, while the trailing twelve-month figure through Dec 2018 was -$8.0 million (up 69.25% YoY) and the FY2025 annual result came in at -$13.3 million, up 24.87% from the prior year.
- Net Income towards Common Stockholders improved to -$8.0 million in Q2 2017, from -$9.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.1 million in Q4 2015 to a low of -$3055.3 billion in Q4 2013.
- A 5-year average of -$509.2 billion and a median of -$8.5 million in 2016 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2014 — Net Income towards Common Stockholders surged 100.0% — and 2016, when it slumped 76.11%.
- Tracing KZIA's Net Income towards Common Stockholders over 5 years: stood at -$3055.3 billion in 2013, then surged by 100.0% to -$6.4 million in 2014, then gained by 19.57% to -$5.1 million in 2015, then tumbled by 76.11% to -$9.0 million in 2016, then gained by 11.42% to -$8.0 million in 2017.
- The last three Net Income towards Common Stockholders figures came in at -$8.0 million (Q2 2017), -$9.0 million (Q4 2016), and -$9.0 million (Q2 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -8.02 Mn |
| Dec 31, 2016 | -9.05 Mn |
| Jun 30, 2016 | -9.01 Mn |
| Dec 31, 2015 | -5.14 Mn |
| Dec 31, 2014 | -6.39 Mn |
| Dec 31, 2013 | -3,055.26 Bn |
| Oct 8, 2012 | -11.38 Mn |
| Dec 31, 2011 | -932,188.32 |
| Dec 31, 2010 | -5.15 Mn |
| Nov 26, 2009 | -5.71 Mn |
| Aug 25, 2009 | -5.18 Mn |